Alice Melão,  —

Universal screening to identify socioeconomic needs of children and families affected by sickle cell disease can help to address their specific difficulties, and ultimately improve the healthcare of those with the disease, a study suggests. The study, “Universal screening for social determinants of health in pediatric sickle…

Treatment with voxelotor, Global Blood Therapeutics’ lead therapy candidate, can markedly reduce both hemolysis — the destruction of red blood cells — and anemia in adolescents and adults with sickle cell disease (SCD), results from the Phase 3 HOPE trial show. Voxelotor also was found to significantly increase the…

Development of problem-solving skills may help adolescents with sickle cell disease prepare for the transition to adulthood and also improve their ability to self-manage their health. Researchers at the Boston University Medical Center conducted a study to gain better insight on the perspectives of sickle cell disease (SCD)…

Acute vaso-occlusive pain is associated with the onset of menstruation, and about 25% of the women with sickle cell disease can differentiate these episodes from menstrual-cramp pain, a study found. Findings in the study, “Acute Vaso-Occlusive Pain is Temporally…

Global Blood Therapeutics’ lead therapeutic candidate voxelotor can induce rapid, robust, and sustained improvements in the amount of hemoglobin in adolescents and adults with sickle cell disease (SCD), according to interim results from the first part of a Phase 3 trial. The latest results of GBT’s clinical…

Hemolytic transfusion reactions, a serious complication of red blood cell transfusion, can be difficult to diagnose in patients with sickle cell disease and even be misinterpreted as severe vaso-occlusive crisis. A report published in the journal Transfusion highlights the importance of accurate and prompt diagnosis of such complications in…

Modus Therapeutics is going to launch a Phase 1 clinical study in the United States to evaluate the potential of its lead candidate sevuparin for the treatment of sickle cell disease (SCD). In the trial, the company will broaden the clinical scope and usefulness of sevuparin to treat…

Children with sickle cell disease who experience obstructive sleep apnea (OSA), a breathing disorder during sleep, are at risk of developing additional health problems, according to researchers. Their study, “Comorbid obstructive sleep apnea and increased risk for sickle cell disease morbidity,” was published in Sleep and…

Once-daily treatment with voxelotor, Global Blood Therapeutics’ lead therapy candidate, can effectively increase the amount of hemoglobin in about 58% of patients with sickle cell disease (SCD) in just 12 weeks, according to results from Part A of a Phase 3 trial. Supported by these positive results, the company…

Negative experiences with a racial connotation are common among adolescents and young adults with sickle cell disease (SCD), Connecticut Children’s Medical Center researchers showed in a recent study. In the United States, sickle cell affects mainly African-Americans, and is historically perceived in the medical community as a “black disease.”…